EP3848388A4 - Fusionspolypeptid mit einer polypeptidregion, die o-glycosyliert werden kann - Google Patents
Fusionspolypeptid mit einer polypeptidregion, die o-glycosyliert werden kann Download PDFInfo
- Publication number
- EP3848388A4 EP3848388A4 EP19857094.7A EP19857094A EP3848388A4 EP 3848388 A4 EP3848388 A4 EP 3848388A4 EP 19857094 A EP19857094 A EP 19857094A EP 3848388 A4 EP3848388 A4 EP 3848388A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- glycosylated
- region
- fusion
- fusion polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 title 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 230000004927 fusion Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180105741 | 2018-09-05 | ||
PCT/KR2019/011409 WO2020050626A1 (ko) | 2018-09-05 | 2019-09-04 | O-글리코실화 가능한 폴리펩타이드 영역을 포함하는 융합 폴리펩타이드 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3848388A1 EP3848388A1 (de) | 2021-07-14 |
EP3848388A4 true EP3848388A4 (de) | 2021-11-17 |
Family
ID=69723156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19857094.7A Pending EP3848388A4 (de) | 2018-09-05 | 2019-09-04 | Fusionspolypeptid mit einer polypeptidregion, die o-glycosyliert werden kann |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210340281A1 (de) |
EP (1) | EP3848388A4 (de) |
JP (2) | JP2021535746A (de) |
KR (1) | KR102263105B1 (de) |
CN (1) | CN112654637A (de) |
WO (1) | WO2020050626A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210113482A (ko) | 2020-03-05 | 2021-09-16 | 주식회사 엘지에너지솔루션 | 열 폭주 현상 발생 시 냉각수가 배터리 모듈의 내부로 투입될 수 있는 구조를 갖는 배터리 팩 및 이를 포함하는 ess |
CN114933646A (zh) * | 2022-06-22 | 2022-08-23 | 南通市第一老年病医院(上海大学附属南通医院、南通市第六人民医院、南通市肺科医院) | Smagp蛋白多肽构建及其抗脂肪性肝病活性的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017198435A1 (en) * | 2016-05-20 | 2017-11-23 | Octapharma Ag | Glycosylated vwf fusion proteins with improved pharmacokinetics |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02213A (ja) | 1987-10-19 | 1990-01-05 | Taiho Yakuhin Kogyo Kk | 生理活性ペプチド持続製剤 |
JPH01287041A (ja) | 1988-05-13 | 1989-11-17 | Rooman Kogyo:Kk | 徐放性製剤 |
US5416017A (en) | 1990-05-18 | 1995-05-16 | The Scripps Research Institute | Cholera toxin gene regulated by tissue-specific promoters |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
KR100545720B1 (ko) * | 2004-05-31 | 2006-01-24 | 메덱스젠 주식회사 | 당화된 면역글로불린 및 이를 포함하는 면역접합체 |
EP2662449B1 (de) * | 2007-05-30 | 2017-02-15 | Postech Academy-Industry- Foundation | Immunglobulinfusionsproteine |
EP2162535A4 (de) | 2007-06-04 | 2011-02-23 | Novo Nordisk As | O-verknüpfte glykosylierung unter verwendung von n-acetylglucosaminyl-transferasen |
RU2503688C2 (ru) * | 2009-04-22 | 2014-01-10 | Алтеоген, Инк | Слитый белок или пептид с увеличенным временем полужизни in vivo, поддерживаемый за счет замедленного высвобождения in vivo, и способ увеличения времени полужизни in vivo с его применением |
RU2012127383A (ru) * | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
KR101868139B1 (ko) | 2010-11-30 | 2018-06-15 | 주식회사 엘지화학 | 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터 |
KR102092225B1 (ko) | 2014-04-30 | 2020-03-23 | 주식회사 엘지화학 | 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터 |
CN106256835A (zh) * | 2016-08-19 | 2016-12-28 | 安源医药科技(上海)有限公司 | 高糖基化人生长激素融合蛋白及其制备方法与用途 |
-
2019
- 2019-09-04 EP EP19857094.7A patent/EP3848388A4/de active Pending
- 2019-09-04 KR KR1020190109551A patent/KR102263105B1/ko active IP Right Grant
- 2019-09-04 WO PCT/KR2019/011409 patent/WO2020050626A1/ko unknown
- 2019-09-04 CN CN201980057872.2A patent/CN112654637A/zh active Pending
- 2019-09-04 US US17/273,591 patent/US20210340281A1/en active Pending
- 2019-09-04 JP JP2021512245A patent/JP2021535746A/ja active Pending
-
2023
- 2023-04-19 JP JP2023068787A patent/JP2023086836A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017198435A1 (en) * | 2016-05-20 | 2017-11-23 | Octapharma Ag | Glycosylated vwf fusion proteins with improved pharmacokinetics |
Non-Patent Citations (2)
Title |
---|
"Therapeutic Proteins", 6 February 2012, WILEY-BLACKWELL, Weinheim, Germany, ISBN: 9783527328499, article FARES FUAD: "Half-Life Extension through O-Glycosylation : Strategies to Modulate Their Plasma Half-Lives", pages: 81 - 94, XP055848858, DOI: 10.1002/9783527644827.ch5 * |
FARES F ET AL: "Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 89, no. 10, 15 May 1992 (1992-05-15), pages 4304 - 4308, XP002110929, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
JP2021535746A (ja) | 2021-12-23 |
JP2023086836A (ja) | 2023-06-22 |
KR20200027903A (ko) | 2020-03-13 |
EP3848388A1 (de) | 2021-07-14 |
KR102263105B1 (ko) | 2021-06-09 |
WO2020050626A1 (ko) | 2020-03-12 |
CN112654637A (zh) | 2021-04-13 |
US20210340281A1 (en) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202011743SA (en) | Fusion proteins comprising progranulin | |
EP3806889A4 (de) | Zytokinfusionsproteine und verwendungen davon | |
EP3743438A4 (de) | Cytokinfusionsproteine | |
EP3880814A4 (de) | Fusionsprotein | |
EP3454832A4 (de) | Gdf15-fusionsproteine und verwendungen davon | |
EP3341009A4 (de) | Chimäre polypeptidanordnung sowie verfahren zur herstellung und verwendung davon | |
EP3287470A4 (de) | Neuartiges rekombinantes bifunktionelles fusionsprotein sowie herstellung und anwendung davon | |
EP3802812A4 (de) | Gegen rna gerichtete fusionsproteinzusammensetzungen und verfahren zu deren verwendung | |
EP3757218A4 (de) | Fusionsprotein | |
EP3274457A4 (de) | Follistatin-assoziierte fusionsproteine und verwendungen davon | |
EP3861120A4 (de) | Rekombinantes typ-i-crispr-cas-system | |
IL289887A (en) | A fusion polypeptide for immunotherapy | |
EP3199179A4 (de) | Formulierung aus rekombinantem fusionsprotein | |
EP3199555A4 (de) | Formulierung aus rekombinantem fusionsprotein | |
EP3722305A4 (de) | Hm-3-fusionsprotein und verwendung davon | |
EP3882277A4 (de) | Fusionsprotein und verwendung davon | |
EP3836959A4 (de) | Anti-angiogenese-fusionsprotein und verwendungen davon | |
IL271268A (en) | A fusion protein that extends half-life | |
SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
EP3668551A4 (de) | Apom-fc-fusionsproteine und verwendung davon | |
EP3895023A4 (de) | Makro-op-fusion | |
GB202201003D0 (en) | Fusion polypeptide and use thereof | |
GB201819200D0 (en) | Polypeptide and uses thereof | |
IL279057A (en) | Antimicrobial fusion proteins containing endolysin and their uses | |
EP3843755A4 (de) | Flt3l-basierte chimäre proteine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210401 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20211018 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/68 20170101ALI20211012BHEP Ipc: A61K 38/27 20060101ALI20211012BHEP Ipc: A61K 38/26 20060101ALI20211012BHEP Ipc: C07K 16/00 20060101ALI20211012BHEP Ipc: C07K 14/61 20060101ALI20211012BHEP Ipc: C07K 14/605 20060101AFI20211012BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230307 |